|
| 37774741 | RANO 2.0: The revised Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future. | Neuro Oncol | 2024 |
| 37665776 | Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group. | Neuro Oncol | 2024 |
| 37551745 | CDK7 and CDK9 inhibition interferes with transcription, translation, and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity. | Neuro Oncol | 2024 |
| 35961053 | Prognostic validation of a new classification system for extent of resection in glioblastoma: AÂ report of the RANO resect group. | Neuro Oncol | 2023 |
| 37490232 | Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases. | J Neurooncol | 2023 |
| 38015375 | Development of a "Geo-Tagged" tumor sample registry: intra-operative linkage of sample location to imaging. | J Neurooncol | 2023 |
| 37488293 | Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. | Nat Med | 2023 |
| 37749305 | The impact of opioid administration for post gamma knife radiosurgery frame removal: a prospective quality-improvement study. | J Neurooncol | 2023 |
| 37702792 | Let the Guard Down: cAMP Activators Can Improve Immunotherapy in GBM. | Cancer Immunol Res | 2023 |
| 37657227 | Stereotactic radiosurgery and anti-PD-1Â +Â CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases. | Eur J Cancer | 2023 |
| 37774317 | RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. | J Clin Oncol | 2023 |
| 37922934 | A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups. | Lancet Oncol | 2023 |
| 35657335 | Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539. | Neuro Oncol | 2023 |
| 35849035 | Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. | Neuro Oncol | 2023 |
| 37188783 | Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. | Nat Med | 2023 |
| 37253096 | Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group. | Neuro Oncol | 2023 |
| 37252795 | The MIF promoter SNP rs755622 is associated with immune activation in glioblastoma. | JCI Insight | 2023 |
| 37183658 | Correction: Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets. | Cancer Res | 2023 |
| 36617262 | Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. | Neuro Oncol | 2023 |
| 36640127 | Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial. | Neuro Oncol | 2023 |
| 36702828 | Author Correction: Federated learning enables big data for rare cancer boundary detection. | Nat Commun | 2023 |
| 36455228 | Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study. | Neuro Oncol | 2023 |
| 34669082 | The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs. | Breast Cancer Res Treat | 2022 |
| 35733635 | Use of virtual magnetic resonance imaging to compensate for brain shift during image-guided surgery: illustrative case. | J Neurosurg Case Lessons | 2022 |
| 35580289 | A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology. | Am Soc Clin Oncol Educ Book | 2022 |
| 35561836 | Leveraging the neurosurgical operating room for therapeutic development in NeuroOncology. | Adv Drug Deliv Rev | 2022 |
| 35561283 | Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline. | J Clin Oncol | 2022 |
| 36470898 | Federated learning enables big data for rare cancer boundary detection. | Nat Commun | 2022 |
| 36367630 | Patient satisfaction and cost savings analysis of the telemedicine program within a neuro-oncology department. | J Neurooncol | 2022 |
| 36358918 | Replicative Instability Drives Cancer Progression. | Biomolecules | 2022 |
| 36033542 | Molecular determinants of outcomes in meningiomas. | Front Oncol | 2022 |
| 36130567 | NTRK3 gene fusion in an adult ganglioglioma: illustrative case. | J Neurosurg Case Lessons | 2022 |
| 36325373 | <i>TERT</i> promotor status does not add prognostic information in <i>IDH</i>-wildtype glioblastomas fulfilling other diagnostic WHO criteria: A report of the RANO <i>resect</i> group. | Neurooncol Adv | 2022 |
| 36009108 | The NXDC-MEN-301 Study on 5-ALA for Meningiomas Surgery: An Innovative Study Design for the Assessing the Benefit of Intra-Operative Fluorescence Imaging. | Brain Sci | 2022 |
| 35092434 | Surgical and anatomic factors predict development of leptomeningeal disease in patients with melanoma brain metastases. | Neuro Oncol | 2022 |
| 35311078 | Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies. | Front Oncol | 2022 |
| 35213727 | A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. | Neuro Oncol | 2022 |
| 35275197 | Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. | Clin Cancer Res | 2022 |
| 34999836 | Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. | Neuro Oncol | 2022 |
| 34932393 | Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. | J Clin Oncol | 2022 |
| 35020909 | Balancing maximal resection and functional preservation in surgery for low-grade glioma. | Neuro Oncol | 2022 |
| 32678879 | CODEL: phase III study of RT, RTâ¿¿+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. | Neuro Oncol | 2021 |
| 33742358 | Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases. | J Neurooncol | 2021 |
| 33740099 | Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. | Acta Neuropathol | 2021 |
| 33542075 | Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome. | Clin Cancer Res | 2021 |
| 33819718 | Evidence-based recommendations on categories for extent of resection in diffuse glioma. | Eur J Cancer | 2021 |
| 33561551 | A Prospective Validation Study of the First 3D Digital Exoscope for Visualization of 5-ALA-Induced Fluorescence in High-Grade Gliomas. | World Neurosurg | 2021 |
| 33781509 | Therapeutic Delivery to Central Nervous System. | Neurosurg Clin N Am | 2021 |
| 33863808 | Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. | Clin Cancer Res | 2021 |
| 33611708 | Convection-enhanced drug delivery for glioblastoma: a review. | J Neurooncol | 2021 |